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This paper presents a practical clinical application of a quantitative pharmacokinetic model to study histologically confirmed and graded invasive human breast tumours. The hypothesis was that, given a documented difference in capillary permeability between benign and malignant breast tumours, a relationship between permeability-related DCE-MRI parameters and tumour aggressiveness persists within invasive breast carcinomas. In addition, it was hypothesised that pharmacokinetic parameters may demonstrate stronger correlation with prognostic factors than the more conventional black-box techniques, so a comparison was undertaken.
Significant correlations were found between pharmacokinetic and black-box parameters in 59 invasive breast carcinomas. However, statistically significant variation with tumour grade was only demonstrated in two permeability related pharmacokinetic parameters: k ep (p<0.05) and K trans (p<0.05), using one-way analysis of variance. Parameters k ep , and K trans were significantly higher in Grade 3 tumours then in low grade tumours. None of the measured DCE-MRI parameters varied significantly between Grade 1 and Grade 2 tumours.
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Main Text

Introduction
The blood circulation at the capillary level, or microcirculation, is determined by the metabolic activity of the tissue. In pathological processes (such as tumour genesis), the microcirculation becomes altered. There can be an increase in microvascular density resulting from the growth of new capillary networks (angiogenesis) as well as vasodilatation of existing vessels. With the relatively recent Federal Drug Administration's approval of drugs to target specifically angiogenesis, there is likely to be a requirement to monitor, non-invasively, the levels of angiogenic activity. Compartmental modelling using an MRI contrast agent gadopentetate dimeglumine (Gd-DTPA) and dynamic MRI acquisition offer the opportunity to investigate non-invasively and quantitatively the associated pharmacokinetics and hence the degree of angiogenic activity.
Gd-DTPA is an extracellular contrast agent which selectively alters the magnetic resonance signal intensity throughout its distribution volume which consists of plasma and extravascular extracellular fluid. Physiological parameters which determine tissue microcirculation have a direct influence on the resulting local bulk tissue concentration of Gd-DTPA following intravenous administration. It is therefore possible to monitor the patho-physiological status of tissues by measuring the temporal variation of the MR signal and qualitative information can be obtained from viewing the changes in image contrast. More importantly, it is also possible to obtain quantitative information associated with angiogenesis by mathematical analysis of dynamic contrast-enhanced MRI (DCE-MRI). The investigation of angiogenesis using DCE-MRI techniques can be divided into two fundamentally different groups: the so-called black-box methods and the more complex pharmacokinetic methods.
In black-box methods, the effect of Gd-DTPA is quantified in terms of heuristic, descriptive parameters describing the degree and the time course of enhancement [1] [2] [3] [4] [5] . These black-box parameters include maximal enhancement (ME), initial rate of enhancement (IRE), time to peak (TTP) and wash out slope (WOS). Arguably, this method of analysis does not utilise optimally the available data as information from only selected parts of the dynamic curves are used. Furthermore, it is not possible to correlate findings obtained by different pulse sequences or to compare parameters 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 3 measured in different centres. In quantifying the extent of Gd-DTPA induced contrast enhancement, no presumptions are made about the underlying physical or physiological processes. Although these parameters are certainly related to the physiological parameters that govern tissue microcirculation, the form of this relationship is not considered.
In contrast, the pharmacokinetic methods for quantitative analysis of DCE-MRI provide a framework that can be used to link the physics of MRI signal acquisition and the underlying patho-physiology that governs Gd-DTPA kinetics [6] [7] [8] [9] . Pharmacokinetic (or compartmental) modelling of Gd-DTPA kinetics allows quantification of physiologically relevant parameters such as the volume of the extravascular extracellular space and capillary permeability. The development of methods for the quantification of DCE-MRI based on pharmacokinetic modelling has largely centred on cancer applications and the assessment of blood brain barrier integrity. Within the context of pharmacokinetic modelling it is theoretically possible to separate the influence of physical and physiological parameters on the measured changes of signal intensity in DCE-MRI, thus enabling an assessment of physiological parameters that characterise pathological microcirculation.
Since its introduction into clinical practice by Heywang-Kobruner in 1986 [10] , DCE-MRI has almost unequivocally demonstrated high sensitivity for detection of breast cancer [11] . The main limitation of DCE-MRI in the investigation of breast lesions lies in its low specificity and the majority of studies in this field centred on the design of methods for improving the distinction between malignant and benign breast lesions. The most basic criterion for the differentiation between benign and malignant lesions is the presence or absence of enhancement; this, however, yields a specificity of only 37% [12] . Particularly problematic is the differentiation between benign fibroadenomas, ductal carcinoma in situ (DCIS), and some of the less angiogenesis-dependent types of cancer (such as invasive lobular carcinomas [13] ). Improvement in DCE-MRI specificity in breast cancer (to 75-85%) can be achieved by its integration with other diagnostic findings and the formulation of precise inclusion criteria [13, 14] . The first reports of pharmacokinetic analysis of DCE-MRI were published in 1990 and 1991 by three independent European research groups in Copenhagen [7] , Heidelberg [6] and London [9] . They applied this technique to the assessment of the breakdown of the blood-brain barrier in multiple sclerosis [7, 9] and brain tumours [6, 7] . The potential of this approach for the assessment of microcirculatory properties of the tissues in a variety of other pathological states was quickly recognised. All subsequent models reported in the literature presented variations of these three principal models without radically changing the underlying methodology. Pharmacokinetic analysis of DCE-MRI was applied to the assessment of breast cancer [15] [16] [17] , cervical cancer [18] , colorectal cancer [19] and heart disease [20] [21] [22] .
Although the three principal approaches rely on a common set of assumptions, they differ in the way the final formulation of the model-predicted tissue response curve is represented as a function of physiological parameters, and in the way these parameters are labelled and interpreted [23] . The key differences in the practical implementation of these models are in the treatment of the temporal variation of the Gd-DTPA concentration in plasma, the choice of input function (mode of injection) and the measurement of native (pre-contrast) longitudinal relaxation time T1.
Although DCE-MRI was initially applied to the assessment of brain lesions, it has subsequently been used in the evaluation of a variety of tumours, with the research into Gd-DTPA pharmacokinetics in breast tumours being particularly prominent. Pharmacokinetic analysis was applied in several clinical studies of DCE-MRI in breast lesions where the primary aim of the quantitative analysis was the differentiation between benign and malignant tumours. Significantly higher permeability-related quantifiers of DCE-MRI were reported in invasive breast carcinomas than in benign lesions, although a variable degree of overlap between these groups of lesions was also noted in all published studies, regardless of the choice of the analysis method [24] [25] [26] [27] [28] [29] [30] .
A comparison between black-box and pharmacokinetic analysis of DCE-MRI has been only sporadically reported the literature and the results of these comparisons are equivocal. Müller-Schimpfle et al [31] , for example, found that the application of pharmacokinetic modelling did not 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5 result in the improvement in the discrimination between benign and malignant breast lesions when compared to black-box assessment. Hulka [27] and Mussurakis [24] , on the other hand, reported that their pharmacokinetic parameters allowed a more specific classification of breast cancer lesions than black-box measurements (such as ER, ME and wash-out slope WOS). Only a few studies have attempted to directly correlate DCE-MRI findings with prognostic factors such as tumour grade and nodal status in clinical studies of breast cancer [32] [33] [34] [35] [36] . None of these studies included pharmacokinetic analysis of DCE-MRI. Their results appear to be inconclusive and contradictory. Whilst Mussurakis [33] and Bone [35] found a significant correlation between DCE-MRI and prognostic factors, Fischer [34] and Stomper [32] found no correlation between them.
Different acquisition and sampling protocols have been employed in each of these studies, as well as different methods for quantitative analysis of DCE-MRI. Furthermore, there was a considerable variation in the number of patients/lesions studied, their histological mix, the method used for grading as well as the choice of prognostic factors that DCE-MRI was compared with (tumour grade, nodal status, DNA S-phase percentage as well as various immunohistochemical prognostic indicators). The temporal resolution of DCE-MRI acquisitions used in these studies ranged from 12 seconds [33] , to seven minutes [35] with tissue coverage ranging from four targeted sagittal slices [33] to 64 transverse slices encompassing both breasts [35] .
This paper presents a practical clinical application of a quantitative pharmacokinetic model [37] to study histologically confirmed and graded invasive human breast carcinomas and to investigate the capacity of pharmacokinetic measurements of permeability to reflect histological tumour grade and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 6 node status. The hypothesis was that given a documented difference in capillary permeability between benign and malignant breast tumours, a relationship between permeability-related DCE-MRI parameters and tumour aggressiveness persists within invasive breast carcinomas. In addition it was hypothesised that pharmacokinetic parameters may demonstrate a stronger correlation with prognostic factors than the more conventional black-box techniques so a comparison was undertaken.
Methods
Pharmacokinetic model
After intravenous injection, Gd-DTPA is rapidly distributed throughout the plasma volume and extravasated into the extracellular space. There is evidence that no metabolic trapping of Gd-DTPA occurs within the body and that it is completely eliminated in an unchanged form by renal excretion [37] . The pharmacokinetic modelling technique used in this paper combines the features of two earlier methods of Brix [6] and Tofts [8, 9] . This model [38] describes the temporal variation of contrast agent concentration in the tissue of interest C t (t), as a function of two pharmacokinetic parameters: v e , and k ep , as shown in equation 1. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 where: v e is the fractional volume of extravascular, extra cellular fluid (unit free fraction) k ep is the fractional transfer rate (expressed in min
k is the fractional elimination rate of 0.058 min -1 quoted by Weinmann et al [37] a 1 and a 2 were determined from published data [37] and have the following values: a 1 = 3.99 kg l -1 , a 2 = 4.78 kg l -1 [9] D is the injected dose of Gd-DTPA per kg body weight (D = 0.1 mmol kg
T is the effective duration of the infusion  = t for t T and  = T for t >T For a spoiled gradient echo acquisition sequence, with repetition time TR, flip angle , the following approximation can be used at low concentrations C t (t) to represent temporal variation of normalised signal intensity following intravenous injection of Gd-DTPA:
where:
SI (t) is the signal intensity at time t SI 0 is the pre-injection signal intensity (i.e. t=0) 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 a = [(exp( -TR / T1 ))/(1 -exp( -TR / T1 ))] TR α Pre-contrast longitudinal relaxation time (T1) can be measured or an assumed fixed value can be used.
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The three pharmacokinetic parameters (K trans , v e , and k ep ) were calculated for each dynamic curve derived from a user-selected ROI. All processing was performed using a computer program for nonlinear least squares fitting employing the Levenberg-Marquardt algorithm adapted from Press [41] .
The program was written in C programming language and run on a standard PC. The processing was performed in a single batch operation as no user input was required.
Patients MRI examination of the breasts was performed in patients with breast lesions where conventional triple assessment (X-ray mammography, ultrasound and clinical examination) did not provide conclusive diagnosis and where further information about the extent of a known lesion and/or possible multifocality was being sought. The study was approved by the regional ethics review board and a written informed consent was obtained from every patient. From the total of 255 consecutive patients who underwent the MRI examination, surgery was subsequently carried out in 66 cases. A full pathology report, including tumour grade and lymph node status, was available for 53 patients (60 lesions). Tumour grading was performed using the Nottingham Prognostic Index for primary breast cancer [42] . In one examination, quantitative analysis was not possible due to excessive patient motion.
Full DCE-MRI analysis was undertaken retrospectively in 59 lesions (in 52 patients). All patients were female with a median age of 55 (ranging from 32 to 80). The lesions were classified according to their histological grade into three groups. Twelve lesions were found to be Grade 1 tumours, twenty-nine were Grade 2 and eighteen were Grade 3 tumours. Thirty lesions had negative node status and twentynine were node positive. Forty-four lesions were classified as invasive ductal carcinomas not otherwise specified (NOS), eleven were invasive lobular carcinomas, two were invasive tubular carcinomas and two were invasive mucinous carcinomas. Thirty-four out of fifty-nine lesions had a significant in-situ (DCIS) component. Table 1 presents a summary of the pathology grading and lymph node status for the set of fifty-nine evaluated lesions. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11
Following the inspection of parametric maps, the most representative (usually central) cross section was identified by a trained radiologist and a single circular 16-voxel ROI was placed close to the lesion rim and away from the necrotic, central areas, if present (Figure 3 ). Figure 4 illustrates dynamic curves extracted from two different lesions and the superimposed least squares lines obtained after non-linear fitting of the experimental data to the pharmacokinetic model. The corresponding pharmacokinetic and black-box parameters are listed in Table 2 .
Statistical analysis
SPSS statistical software package (Version 13.0, SPSS, Chicago, IL) was used for statistical analysis.
All statistical tests were performed at  = 0.05 confidence level.
Results
The technique worked robustly in this group of patients, adding only 5 minutes on to the investigation time. Of all the tumours and patients studied the technique was only unsuccessful on one occasion (due to excessive patient motion).
A summary of the black-box and pharmacokinetic parameters is presented in Tables 3 and 4 respectively. The mean values of measured parameters and their standard deviations are listed for each of the three subgroups. A pattern can be seen with a number of parameters (IRE, WOS, K trans , k ep ) with the parameter value changing in a consistent manner when compared to tumour grade. However, when a comparison is made of the pharmacokinetic and black-box parameters for the three different tumour groups using one way analysis of variance, statistically significant variation with tumour grade was only detected in K trans (p<0.005) and k ep (p<0.05), though the parameter WOS approaches significance (p=0.054).
The summary of results of the post-hoc analysis of the differences between individual groups of measurements is presented in Table 5 . A Least Significant Difference correction for multiple comparisons was used. Whilst there were no significant differences between Grade 1 and Grade 2   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 tumours, Grade 3 tumours were significantly different from Grade 1 and Grade 2 tumours, with respect to k ep and K trans .
The correlation of the DCE-MRI parameters with tumour grade and with each other is listed in Table   6 . There are significant correlations between tumour grade and WOS, k ep and K trans (p<0.01) and IRE (p<0.05). K trans exhibited the highest degree of correlation with tumour grade (Spearman's  = 0.473 p <0.0005 ). The data for K trans for each tumour group is plotted in Figure 5 .
There was no significant association between DCE-MRI parameters and nodal status (Student's t-test, p>0.05). Furthermore, groups with and without a significant DCIS component also did not vary significantly (Student's t-test, p>0.05).
Discussion
In our study, the pharmacokinetic parameter K trans demonstrated a stronger relationship with tumour grade than the conventional black-box parameters, suggesting greater sensitivity to differences in microcirculation between different tumour grades. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 grade or nodal status. Furthermore, the proportion of high-grade tumours and tumours of different histological type will have influenced the mean values of K trans and v e measured in all these studies.
Prior to undertaking this study a comparable measurement of permeability in different histological grades of human breast cancer had not, to our knowledge, been reported in the literature. Our measurements are in broad agreement with permeability-related measurements in invasive breast carcinomas in humans reported elsewhere in studies involving an unspecified mix of histological grades and nodal involvement [16, 28] . [32, 36] . However, their studies included only a small number of subjects, and the imaging volume encompassed only five contiguous slices. Fischer et al [34] conducted a large study but employed a sub-optimal acquisition protocol, with respect to both temporal resolution (1.5 minutes) and T1 sensitivity. In two studies where simple enhancement ratios displayed significant association with tumour grade [33, 35] and nodal status [33] , T1 sensitivity was somewhat higher than that achieved by our acquisition protocol . Their superior T1 sensitivity, however, was associated with the concomitant loss of spatial coverage [33] and temporal resolution [35] . The present study provided a compromise between the conflicting requirements for high temporal and spatial resolution, tissue coverage and T1 sensitivity, all of which are important for determining the utility of breast cancer DCE-MRI examinations.
Pharmacokinetic analysis of DCE-MRI was put forward as a tool for non-invasive monitoring of the effects of neoadjuvant chemotherapy in breast cancer and the reduction in K trans was associated with positive response to therapy [44, 45] . However, the reports presented in the literature to date are 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 contradictory. Whereas Manton et al report that pharmacokinetic parameters had no prognostic value [46] , Padhani et al found that the change in K trans was an accurate predictor of response [47] .
In the present study, all lesions were evaluated by MRI before surgical excision without the administration of pre-surgical (neoadjuvant) chemotherapy. Successful neoadjuvant chemotherapy could be viewed as an effective downgrading of the tumour (e.g. from Grade 3 to Grade 2, or from Grade 2 to Grade 1). Therefore, our measurements of DCE-MRI pharmacokinetic parameters in graded primary breast carcinomas may offer an insight into the mechanisms involved in the monitoring of the effects of neoadjuvant chemotherapy by pharmacokinetic analysis of DCE-MRI.
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